Want to see TVGN full AI Analyst Report?
Top Page
Tevogen Bio Holdings
(NASDAQ:TVGN)
Select Model
Select Model
Rating:48Neutral
Price Target:
$7.00
▲(2.79% Upside)
Action:Reiterated
Date:10/09/26
The score is held down primarily by weak financial performance (no revenue, continued losses and cash burn, and negative equity indicating elevated funding/dilution risk). Technicals are largely neutral with slightly negative momentum and a challenged longer-term trend. Corporate events provide a modest offset, led by regained Nasdaq compliance removing a key overhang, but they do not fully counterbalance the underlying financial risk.
Positive Factors
Lower Debt
The substantial reduction in debt improves the company’s leverage profile and reduces fixed financing pressure compared with earlier periods. This gives management more flexibility to direct future capital toward clinical translation, platform development, and potential commercialization rather than debt service.
Negative Factors
Pre-Revenue Model
Zero reported revenue indicates Tevogen is still pre-commercial and has not yet demonstrated product-sales traction. Its biotechnology strategy therefore depends on successful clinical translation and eventual commercialization, leaving near-term financial performance disconnected from operating revenue.
Read all positive and negative factors
Positive Factors
Negative Factors
Lower Debt
The substantial reduction in debt improves the company’s leverage profile and reduces fixed financing pressure compared with earlier periods. This gives management more flexibility to direct future capital toward clinical translation, platform development, and potential commercialization rather than debt service.
Read all positive factors
Tevogen Bio Holdings (TVGN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$42.26M
Dividend YieldN/A
Average Volume (3M)6.69K
Price to Earnings (P/E)―
Beta (1Y)0.97
Revenue GrowthN/A
EPS Growth36.06%
CountryUS
Employees18
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-5.83
Shares Outstanding6,511,540
10 Day Avg. Volume4,364
30 Day Avg. Volume6,691
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-6.68
Price to Sales (P/S)0.00
P/FCF Ratio-4.44
Enterprise Value/Market Cap0.92
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-189.46
Enterprise Value/Ebitda-1.85
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-10.14
Revenue Forecast (FY)N/A
Tevogen Bio Holdings Business Overview & Revenue Model
Company Description
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precisio...
Tevogen Bio Holdings Financial Statement Overview
Summary
Income Statement
10
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
9
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -204.98K | 0.00 | -403.58K | -378.36K | 0.00 | 0.00 |
| EBITDA | -20.95M | -25.57M | -13.14M | -58.89M | 4.64M | -14.99M |
| Net Income | -21.61M | -26.28M | -10.11M | -60.48M | 4.41M | -15.60M |
Balance Sheet | ||||||
| Total Assets | 4.73M | 4.38M | 3.46M | 5.51M | 7.74M | 7.66M |
| Cash, Cash Equivalents and Short-Term Investments | 1.08M | 552.37K | 1.28M | 1.05M | 5.48M | 7.12M |
| Total Debt | 3.04M | 3.10M | 2.89M | 95.42M | 40.01M | 23.48M |
| Total Liabilities | 13.62M | 12.62M | 10.14M | 99.93M | 41.69M | 24.15M |
| Stockholders Equity | -8.89M | -8.23M | -6.67M | -94.43M | -33.95M | -16.49M |
Cash Flow | ||||||
| Free Cash Flow | -11.63M | -12.39M | -12.00M | -8.30M | -9.13M | -5.38M |
| Operating Cash Flow | -11.57M | -12.33M | -12.00M | -8.17M | -8.66M | -5.27M |
| Investing Cash Flow | -64.44K | -64.44K | 0.00 | -133.00K | -479.04K | -109.73K |
| Financing Cash Flow | 12.03M | 11.66M | 12.23M | 3.87M | 7.50M | 12.50M |
Tevogen Bio Holdings Technical Analysis
Neutral
6.81
Price Trends
6.99
Positive
7.29
Negative
9.10
Negative
Market Momentum
-0.10
Positive
50.92
Neutral
30.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TVGN, the sentiment is Neutral. The current price of 6.81 is below the 20-day moving average (MA) of 7.22, below the 50-day MA of 6.99, and below the 200-day MA of 9.10, indicating a neutral trend. The MACD of -0.10 indicates Positive momentum. The RSI at 50.92 is Neutral, neither overbought nor oversold. The STOCH value of 30.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TVGN.
Tevogen Bio Holdings Risk Analysis
Tevogen Bio Holdings disclosed 76 risk factors in its most recent earnings report. Tevogen Bio Holdings reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Tevogen Bio Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $567.55M | -11.10 | -43.57% | ― | -66.63% | 57.89% | |
56 Neutral | $662.35M | -15.37 | -169.47% | ― | ― | -13.52% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $42.26M | -1.21 | 248.50% | ― | ― | 36.06% | |
47 Neutral | $346.93M | -2.85 | -45.45% | ― | 2.33% | 36.86% | |
46 Neutral | $162.59M | -1.41 | -39.64% | ― | ― | -6.70% |
* Healthcare Sector Average
TVGN
Tevogen Bio Holdings
7.06
-28.70
-80.25%
NKTX
Nkarta
2.22
0.06
2.78%
CCCC
C4 Therapeutics
2.85
0.60
26.67%
STTK
Shattuck Labs
5.66
3.82
207.61%
NVCT
Nuvectis Pharma
20.13
14.17
237.75%
ACTU
Actuate Therapeutics, Inc.
0.68
-7.11
-91.28%
Tevogen Bio Holdings Corporate Events
Delistings and Listing ChangesRegulatory Filings and Compliance
Tevogen Bio Regains Full Nasdaq Listing Compliance
Positive
Sep 30, 2026
On September 29, 2026, Tevogen Inc. received written notice from Nasdaq confirming it had regained compliance with the $50 million minimum market value of listed securities requirement for continued listing on the Nasdaq Global Market. This follow...
Business Operations and StrategyExecutive/Board Changes
Tevogen Bio grants major performance-based executive stock awards
Positive
Sep 16, 2026
On September 14, 2026, Tevogen Inc. granted large restricted stock awards to Chief Executive Officer and Chairperson Ryan Saadi and Chief Financial Officer Kirti Desai under its 2024 Omnibus Incentive Plan. Saadi received 8,000,000 restricted shar...
Delistings and Listing ChangesRegulatory Filings and Compliance
Tevogen Bio regains Nasdaq listing compliance status
Positive
Sep 10, 2026
On September 9, 2026, Tevogen Inc. reported that it had regained compliance with Nasdaq’s $15 million minimum market value of publicly held shares requirement for continued listing on The Nasdaq Global Market. Nasdaq notified the company tha...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Tevogen Bio Shareholders Approve Governance-Enhancing Charter Changes
Positive
Aug 26, 2026
As of July 23, 2026, Tevogen had 6,416,540 common shares outstanding, and on August 24, 2026, the company held its annual shareholders’ meeting, where a quorum was present and all proposals received strong support. Stockholders elected Dr. K...
Business Operations and StrategyRegulatory Filings and Compliance
Tevogen Bio Holdings Rebrands as Tevogen Inc.
Neutral
Jul 30, 2026
On July 29, 2026, Tevogen Bio Holdings Inc. filed a certificate of amendment to change its corporate name to Tevogen Inc., with the new name becoming effective on July 30, 2026. In tandem, the board approved a related bylaws amendment to reflect t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.